{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:05:12Z","timestamp":1774566312965,"version":"3.50.1"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[1998,11,1]],"date-time":"1998-11-01T00:00:00Z","timestamp":909878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Nosocomial pneumonia and acute peritonitis may be caused by a wide array of pathogens, and combination therapy is often recommended. We have previously shown that imipenem-cilastatin monotherapy was as efficacious as the combination of imipenem-cilastatin plus netilmicin in these two settings. The efficacy of imipenem-cilastatin is now compared to that of piperacillin-tazobactam as monotherapy in patients with nosocomial pneumonia or acute peritonitis. Three hundred seventy one patients with nosocomial pneumonia or peritonitis were randomly assigned to receive either imipenem-cilastatin (0.5 g four times a day) or piperacillin-tazobactam (4.5 g three times a day). Three hundred thirteen were assessable (154 with nosocomial pneumonia and 159 with peritonitis). For nosocomial pneumonia, clinical-failure rates in the piperacillin-tazobactam group (13 of 75 [17%]) and in the imipenem-cilastatin group (23 of 79 [29%]) were similar (\n            <jats:italic>P<\/jats:italic>\n            = 0.09), as were the numbers of deaths due to infection (6 in the imipenem-cilastatin group [8%], 7 in the piperacillin-tazobactam group [9%]) (\n            <jats:italic>P<\/jats:italic>\n            = 0.78). For acute peritonitis, clinical success rates were comparable (piperacillin-tazobactam, 72 of 76 [95%]; imipenem-cilastatin, 77 of 83 [93%]). For infections due to\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            , 45 patients had nosocomial pneumonia (21 in the piperacillin-tazobactam group and 24 in the imipenem-cilastatin group) and 10 had peritonitis (5 in each group). In the patients with nosocomial pneumonia, clinical failure was less frequent in the piperacillin-tazobactam group (2 of 21 [10%]) than in the piperacillin-cilastatin group (12 of 24 [50%]) (\n            <jats:italic>P<\/jats:italic>\n            = 0.004). Bacterial resistance to allocated regimen was the main cause of clinical failure (1 in the piperacillin-tazobactam group and 12 in the imipenem-cilastatin group). For the patients with peritonitis, no difference in clinical outcome was observed (five of five cured in each group). The overall frequencies of adverse events related to treatment in the two groups were similar (24 in the piperacillin-tazobactam group, 22 in the imipenem-cilastatin group). Diarrhea was significantly more frequent in the piperacillin-tazobactam group (10 of 24) than in the imipenem-cilastatin group (2 of 22). This study suggests that piperacillin-tazobactam monotherapy is at least as effective and safe as imipenem-cilastatin monotherapy in the treatment of nosocomial pneumonia or peritonitis. In\n            <jats:italic>P. aeruginosa<\/jats:italic>\n            pneumonia, piperacillin-tazobactam achieved a better clinical efficacy than imipenem-cilastatin, due to reduced development of microbiological resistance. Tolerance was comparable, with the exception of diarrhea, which was more frequent with piperacillin-tazobactam.\n          <\/jats:p>","DOI":"10.1128\/aac.42.11.2966","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:29:45Z","timestamp":1539044985000},"page":"2966-2972","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":120,"title":["Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis"],"prefix":"10.1128","volume":"42","author":[{"given":"C.","family":"Jaccard","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Troillet","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Institut Central des Ho\u0302pitaux valaisans, 1951 Sion,2 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Harbarth","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Ho\u0302pital Cantonal Universitaire, 1211 Geneva,3 Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Zanetti","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Aymon","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schneider","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Chiolero","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ricou","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Ho\u0302pital Cantonal Universitaire, 1211 Geneva,3 Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Romand","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Ho\u0302pital Cantonal Universitaire, 1211 Geneva,3 Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Huber","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Ho\u0302pital Cantonal Universitaire, 1211 Geneva,3 Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ambrosetti","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Ho\u0302pital Cantonal Universitaire, 1211 Geneva,3 Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Praz","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Institut Central des Ho\u0302pitaux valaisans, 1951 Sion,2 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lew","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Division of Infectious Diseases, Ho\u0302pital Cantonal Universitaire, 1211 Geneva,3 Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bille","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Glauser","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cometta","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,1"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Acar J. F. F. W. Goldstein and D. Kitzis. 1993. Susceptibility survey of piperacillin alone and in the presence of tazobactam. J. Antimicrob. Ther. 31 (Suppl. A):23\u201328.","DOI":"10.1093\/jac\/31.suppl_A.23"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30059-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.2_Supplement.26S"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.109.4.1019"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2766"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447030-00008"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745251"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Chastre J. F. Fagon and J.-L. Trouillet. 1995. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Clin. Infect. Dis. 21 (Suppl. 3):S326\u2013S327.","DOI":"10.1093\/clind\/21.Supplement_3.S226"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Chow A. F. C. B. Hall J. O. Klein R. B. Kammer R. D. Meyer and J. S. Remington. 1992. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin. Infect. Dis. 15 (Suppl. 1):S62\u2013S88.","DOI":"10.1093\/clind\/15.Supplement_1.S62"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1309"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1108"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.445"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01752970"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.2_Supplement.1S"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30121-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-10-199405150-00004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"DiPiro J. T. and N. S. Forston. 1993. Combination antibiotic therapy in the management of intra-abdominal infection. Am. J. Surg. 165 (Suppl. 2A):82S\u201388S.","DOI":"10.1016\/S0002-9610(05)81211-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.6.4.428"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.538"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90060-3"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.547"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-6553(88)90053-3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745248"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Gorbach S. L. 1993. Treatment of intra-abdominal infections. J. Antimicrob. Ther. 31 (Suppl. A):67\u201368.","DOI":"10.1093\/jac\/31.suppl_A.67"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80611-4"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/20.1.95"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90010-1"},{"key":"e_1_3_2_29_2","first-page":"607","article-title":"Etude prospective randomis\u00e9e contr\u00f4l\u00e9e imip\u00e9nem-cilastatine versus c\u00e9fotaxime-amikacine dans le traitement des infections respiratoires inf\u00e9rieures et des septic\u00e9mies de r\u00e9animations.","volume":"19","author":"Mouton Y.","year":"1990","unstructured":"Mouton Y. Deboscker Y. Bazin C. Fourrier F. Moulront S. Philippon A. Socolevsky C. Suinat J. L. Tondriaux A. Etude prospective randomis\u00e9e contr\u00f4l\u00e9e imip\u00e9nem-cilastatine versus c\u00e9fotaxime-amikacine dans le traitement des infections respiratoires inf\u00e9rieures et des septic\u00e9mies de r\u00e9animations. Presse Med. 19 1990 607 612","journal-title":"Presse Med."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Mouton Y. O. Leroy C. Beuscart C. Chidiac E. Senneville F. Ajana and P. Lecocq. 1993. Efficacy safety and tolerance of parenteral piperacillin\/tazobactam in the treatment of patients with lower respiratory tract infections. J. Antimicrob. Ther. 31 (Suppl. A):87\u201395.","DOI":"10.1093\/jac\/31.suppl_A.87"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30123-7"},{"key":"e_1_3_2_32_2","first-page":"255","article-title":"Piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of intra-abdominal infections.","volume":"176","author":"Niinikoski J.","year":"1993","unstructured":"Niinikoski J. Havia T. Alhava E. P\u00e4\u00e4kk\u00f6nen M. Miettinen P. Kivilaasko E. Haapiainen R. Matikainen M. Laitinen S. Piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of intra-abdominal infections. Surg. Gynecol. Obstet. 176 1993 255 261","journal-title":"Surg. Gynecol. Obstet."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745249"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.6.927"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745250"},{"key":"e_1_3_2_36_2","first-page":"598","article-title":"Prospective randomized study of piperacillin\/tazobactam therapy of surgically treated intra-abdominal infection.","volume":"59","author":"Polk H. C.","year":"1993","unstructured":"Polk H. C. Fink M. P. Laverdiere M. Wilson S. E. Garber G. E. Barie P. S. Hebert J. C. Cheadle W. G. Prospective randomized study of piperacillin\/tazobactam therapy of surgically treated intra-abdominal infection. Am. Surg. 59 1993 598 605","journal-title":"Am. Surg."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.973"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745247"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.1.107"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(16)45982-7"},{"key":"e_1_3_2_41_2","unstructured":"Sieger\n              B.\n              Geckler\n              R.\n          A comparison of meropenem and ceftazidime plus tobramycin in the treatment of hospital-acquired lower respiratory infections\n          Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy.\n          1993\n          640\n          American Society for Microbiology\n          Washington D.C"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199011000-00004"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Solomkin J. S. D. L. Hemsell R. Sweet F. Tally and J. Bartlett. 1992. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Clin. Infect. Dis. 15 (Suppl. 1):S33\u2013S42.","DOI":"10.1093\/clind\/15.Supplement_1.S33"},{"key":"e_1_3_2_44_2","first-page":"280","article-title":"Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection.","volume":"83","author":"Sweet R. L.","year":"1994","unstructured":"Sweet R. L. Subir R. Faro S. O\u2019Brien W. F. Sanphilippo J. S. Mindell S. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet. Gynecol. 83 1994 280 286","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.3.786"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01752974"}],"updated-by":[{"DOI":"10.1128\/aac.43.3.726","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.11.2966","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.11.2966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:42:10Z","timestamp":1645458130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.11.2966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1998,11]]}},"alternative-id":["10.1128\/AAC.42.11.2966"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.11.2966","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,11]]},"assertion":[{"value":"1997-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}